the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:www.galderma.com.

References


Eichenfield LF, et al. Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Late breaking abstract presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27-31, 2026; United States

Nemluvio®U.S. Prescribing Information. Availableonline. Accessed March 2026

Nemluvio®European Medicines Agency. Summary of Product Characteristics. Availableonline. Accessed March 2026

Schoch JJ, et al. Atopic dermatitis: Update on skin-directed management: clinical report.Pediatrics. 2025; 155(6):e2025071812. doi:10.1542/peds.2025-071812

Eichenfield LF, et al. Patient-reported impact of atopic dermatitis on pediatric and adolescent patients with moderate-to-severe disease: results of a real-
=*=*=*=*=*=
当前为第7/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页